Compare NAKA & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAKA | MXCT |
|---|---|---|
| Founded | 2019 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.1M | 155.8M |
| IPO Year | 2023 | 2021 |
| Metric | NAKA | MXCT |
|---|---|---|
| Price | $5.65 | $1.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $13.33 | $4.11 |
| AVG Volume (30 Days) | 167.1K | ★ 1.6M |
| Earning Date | 11-18-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.19 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | $3,833.87 | N/A |
| Revenue Next Year | N/A | $15.53 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.33 | $0.64 |
| 52 Week High | $640.80 | $1.81 |
| Indicator | NAKA | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 35.79 | 45.97 |
| Support Level | $4.38 | $1.02 |
| Resistance Level | $7.59 | $1.54 |
| Average True Range (ATR) | 0.62 | 0.15 |
| MACD | -0.16 | -0.03 |
| Stochastic Oscillator | 11.82 | 3.12 |
Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets. The firm has two principal business segments: Bitcoin Operations, which houses its Bitcoin treasury and is utilized to support investments in other Bitcoin-related companies; Healthcare Operations, which provides a patient-focused healthcare experience that provides patients personalized solutions in order to reduce opioid use and improve health outcomes. The company generates the majority of its revenue from the Healthcare Operations.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.